The biotech said it would use the cash to “further accelerate” a portfolio led by its GLP-1 receptor agonist MET-097, which ...

Tirzepatide shows promise in reducing weight and preventing diabetes progression in people with obesity and prediabetes, with ...

Over the past year, the question has been coming in from everywhere – from my patients and family members, from colleagues ...

"We've seen firsthand how transformative GLP-1 treatments like semaglutide can be for patients' lives. We remain focused on ...

A recent study found semaglutide – the drug known as Ozempic – can improve knee pain in people with obesity and ...

Obesity is a chronic condition and a key risk factor for a range of other health issues, including type 2 diabetes. In a ...

Parents often worry that their child is a poor eater, so health professionals need to know what's normal and when ...

This clinical trial is a randomized, double-blind study designed to enroll 120 patients across four treatment groups. The primary endpoint will evaluate the difference in weight loss of nimacimab ...

The Hormone Diet emphasizes anti-inflammatory foods to help you balance hormones like cortisol and estrogen and lose weight.

Scientists at the University of Copenhagen have discovered a new weight loss drug target that reduces appetite, increases ...

Was this a medical ... phase typically lasts three months. Some people find that they don’t notice shedding until months ...

Powers Health surgical and medical ... their weight loss and overall health. For those who aren’t candidates for surgery or prefer nonsurgical options, we also offer GLP-1 receptor agonists ...